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Standard treatments for nonsmall cell lung cancer (NSCLC), such as surgery, chemotherapy, and radiotherapy, often lead to
disappointing results. Unfortunately, also the various immunotherapeutic approaches so far tested have not produced satisfactory
results to be widely applied in the clinical practice. However, the recent development of new immunomodulatory agents may open
promising therapeutic options. This paper focuses on PF3512676, lenalidomide, and NGR-TNF, that is, drugs belonging to three
diﬀerent classes of immunomodulatory agents, that are also capable to aﬀect tumor blood vessels with diﬀerent mechanisms, and
discusses the potential role of such agents in NSCLC treatment strategy.
1.Introduction
Lung cancer is the leading cause of cancer death in both men
andwomenandoneoftheleadingcausesofdeathworldwide
[1]. Non small cell lung cancer (NSCLC) represents ∼
80% of all types of lung cancer. Most patients present
with locally advanced (stage III) or metastatic (stage IV)
cancer [2, 3]. Despite chemotherapy treatment, sometimes
in combination with radiotherapy, most patients die of
disease progression, due to acquired or intrinsic resistance
to chemotherapeutic drugs. Various immunotherapeutic
approaches have been also attempted, ranging from the use
of nonspeciﬁc immunostimulants like Bacillus Calmette-
Guerin (BCG) to more speciﬁc strategies, unfortunately
often with disappointing results [4, 5]. However, the recent
improvement of our understanding of how the immune
system works, the identiﬁcation of new target antigens,
and the development of new immunomodulators capable
to aﬀect the immune system and the tumor neovasculature
could open new therapeutic options that deserve further
investigation.
This review discusses the potential role of three
immunomodulatory agents that, besides regulating immune
cells, can also aﬀect the tumor neovasculature with diﬀerent
mechanisms and to diﬀerent extent. In particular we discuss:
(a) PF3512676, a Toll-like receptor 9 agonist primarily
endowed of immunomodulatory activity, (b) lenalidomide,
an immunomodulator with antiangiogenic properties and
(c) NGR-TNF, an immunomodulatory agent with strong
vascular damaging activity.
2. PF3512676 (TLR9 Agonist)
Toll like receptors (TLRs) are a family of highly conserved
receptors that regulate innate antigen-speciﬁc immunity
via the recognition of pathogen-associated molecular pat-
tern [6–9]. TLR9 is expressed in endosomes of B and
T lymphocytes, plasmocytoid cells, and dendritic cells
[10]. Immunostimulatory oligonucleotides containing cer-
tain CpG sequence motifs stimulate the innate and adaptive
immune response and have been under investigation for
treating infectious diseases, allergies, asthma, and cancer2 Journal of Oncology
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Figure 1: Proposed mechanism of action of PF-3512676. In the ﬁrst phase, PF-3512676 activates a rapid induction of innate immune
responsethroughTLR9stimulationinBcellandplasmocytoidcells.This mayrestoredefectiveplasmocytoiddendriticcellfunction,induces
IFN secretion (all IFN types), and activates NK and NKT cell. A later induction of adaptive immune response may then occur through
dendritic cell mediated activation of antigen-speciﬁc T cells, monocytes and polymorphonuclear leukocytes, promotion of killer T cells and
production of antibodies by B cells.
[11–16]. Through TLR9 signalling pathway, immunostimu-
latory oligonucleotides activate a complex cascade that leads
to increased production of proinﬂammatory cytokines and
chemokines and stimulation of an immune response with
antitumor eﬀects [17–21]. Bioengineered immunomodula-
tory oligonucleotides have been developed to stimulate the
immune system of various animal species, as well as puriﬁed
and cultured human immune cells [22–24]. Several new
immunomodulatory oligonucleotides have been evaluated
in models of human cancer [25–27]. Among these, PF-
3512676 (ProMune) is particularly promising. It contains
unmethylated cytosine and guanine (CpG) motifs and a
nuclease-resistant phosphorothioate backbone [28]. It is
an agonist of the TLR9 expressed in plasmocytoid cells
and B cells [28]. The anticancer activity of PF-3512676 is
related to direct and indirect immunomodulation of both
innate and adaptive immune responses [29]. Plasmocytoid
dendritic cells stimulated by PF-3512676 express increased
levels of MHC I and II and costimulatory molecules (leading
to improved antigen presentation) secrete cytokines and
chemokines that enhance natural killer (NK) cell activity
directed toward tumor cells, present tumor speciﬁc antigens
and costimulatory molecules to B and T cells, and generate
long-living antigen speciﬁc cytotoxic T-lymphocytes and
antibody responses [30]. A good indicator of activation and
maturation of dendritic cells by PF-3512676 is the produc-
tion of IFNα and the subsequent induction of interferon-
inducible protein 10 (IP-10), an antiangiogenic cytokine
[28, 31]. Furthermore upregulation of CD86 and CD80
on B cells induced by PF-3512676 and secretion of IL-
10 and IL-6 demonstrate its strong stimulatory properties
[30]. A schematic representation of the mechanism of action
of PF-3512676 is shown in Figure 1. The clinical safety
and eﬃcacy of PF-3512676 have been evaluated in 18
clinical studies [30, 32]. Overall, 889 subjects were enrolled
in these trials, where PF3512676 was administered via
subcutaneous, intravenous, intralesional, or intramuscular
routes as monotherapy or in combination with monoclonal
antibodies or with chemotherapeutic agents. Immunological
responses (such as induction of innate/adaptive immune
responses with moderate to abundant cellular inﬁltrates of
lymphocytes proven in tumor biopsies) leading in some
cases to tumor regression were observed in patients with
melanoma, renal cell carcinoma, non-Hodgkin lymphoma
and non small cell lung cancer [28, 30, 33–38]. Focusing
on NSCLC, a phase II study enrolling 112 chemonaive
patients with NSCLC was conducted. The patients received
PF3512676 in combination with platinum and taxane dou-
blet chemotherapy at a dose of 0.2mg/kg, sc, on the 2nd and
3rd weeks of a 3-week chemotherapy cycle [39, 40]. Twenty-
eight (37%) patients had a partial or complete response
with the combination of chemotherapy and PF-3512676
and 7 (19%) with chemotherapy alone. The combination
of chemotherapy and PF-3512676 was well tolerated even
if there was an excess of myelosuppression. The most com-
monly reported PF-3512676 related events were reversible
local injection reactions, such as erythema, pain, induration,
warmthandswelling,orsystemicﬂu-likesymptoms(fatigue,
pyrexia, headache, chills, arthralgia and myalgia). Based on
these preliminary data, two phase III trials were conducted
to test the eﬃcacy of PF-3512676 in combination with
platinum based chemotherapy in advanced NSCLC patients.
Unfortunately, both studies failed to prove the superiority of
the combination after an interim analysis by an independent
data monitoring safety committee [41], showing also a worse
toxicity proﬁle for the PF-3512676 arm [42, 43].
3. Lenalidomide (Immunomodulatory
Imide Drug)
Another promising drug class among immunomodulatory
agents is represented by Immunomodulatory imide DrugsJournal of Oncology 3
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Figure 2: Proposed mechanism of action of lenalidomide. This drug can inhibit endothelial cell migration and adhesion possibly by
downregulating endothelial cell integrins and angiogenesis. Lenalidomide can also induce immunomodulatory eﬀect by activating T
and NKT cells, which in turn release cytotoxic mediators, and by inhibiting the release of proinﬂammatory cytokines in the tumor
microenvironment. The antiangiogenic eﬀect is a major component of lenalidomide antitumor activity in solid tumors.
(the so-called IMiDs). Thalidomide is the IMiDs progenitor.
Second generation IMiDs are lenalidomide, pomalidomide
and ENMD-0995. Thalidomide has emerged as a potent
treatment for several disease entities. Although originally
marketed in Europe as a sedative and antiemetic, reports of
teratogenic eﬀects [44] led to its withdrawal in the market
in 1961 [45]. Thalidomide-associated congenital malfor-
mations were later explained as impaired vasculogenesis
suggesting that a similar mechanism may contribute to
prevent the growth of tumor blood vessels [46, 47]. In the
cancer setting, thalidomide is currently used in multiple
myeloma patients [48].
Lenalidomide is the ﬁrst 2nd generation IMiD to be
approved for clinical use. It has been registered as 2nd line
treatment in association with dexamethasone in patients
withmultiplemyeloma[49].However,thetherapeuticutility
of this drug may not be limited to haematological malig-
nancies. It was synthesized based on the structural backbone
of thalidomide, by adding an amino group at position 4
of the phthaloyl ring and removal of the carbonyl group
of the 4-amino-substituted phthaloyl ring. Such structural
changes were designed to enhance its immunomodulatory
and antitumor activity [49, 50]. Despite the proven clinical
activityoftheIMiDstheexactmechanismoftheirantitumor
activity remains elusive. It is possible that the antitumor
activity of lenalidomide is mediated through multiple non-
mutually exclusive processes that primarily depend on the
type of tumor cells and their microenvironment. Data on
lenalidomide’s mechanism of action, mostly derived from
studies on multiple myeloma and B cell malignancies can
likely be applied also to solid tumors. Lenalidomide has
been shown to inhibit TNF-α [51, 52], IL-6 and other
proapoptotic cytokines and proinﬂammatory mediators [49,
53], and to activate proapoptotic signals triggered by Fas-
mediated cell death, such as caspase-8 (but not caspase-
9) [49]. Lenalidomide downregulates antiapoptotic proteins
like the cellular inhibitor of apoptosis protein 2 and FLICE
inhibitor protein. Nuclear factor-kB is also directly inhibited
by lenalidomide [49]. Lenalidomide is a potent stimulator of
lipopolysaccharide-induced IL-10,aswellascostimulatorsof
T cells that are partially activated through the T-cell receptor,
intheCD8+subset[54,55].Furthermore,itinducesincrease
in IL-2 and IFNγ secretion and upregulation of CD40L
expression on anti-CD3 stimulated T cells, resulting in
activation of natural killer cells, and thus improving host
immunity against tumor cells [56]. Compared to thalido-
mide, lenalidomide is 50 to 2000 times more potent in stim-
ulating T-cell proliferation and activation and 50–100 times
more potent in augmenting IL-2 and IFNγ production [49].
In contrast with PF-3512676, which shows a predominant
immunomodulatory activity, IMiDs are also proapoptotic
agents and strong angiogenesis inhibitors. Indeed, various
in vitro assays have demonstrated the antiangiogenic activity
of IMiDs [57–60]. This activity is believed to be secondary
to the inhibition of secretion of angiogenic cytokines, such
as vascular endothelial growth factor (VEGF) and ﬁbroblast
growth factor (FGF), from both tumor and stromal cells. In
addition, lenalidomide hasbeenshowntoinhibit endothelial
cell migration and adhesion, perhaps by downregulating
endothelial cell integrins [61, 62]. Lenalidomide is reported
to downregulate key cytokines such as TNF-α, IL-6, IL-8 and
VEGF, that is, cytokines which favour tumor cell survival,
proliferation and, possibly, resistance to therapy, mainly by
aﬀecting the tumor vasculature [50]. A schematic represen-
tation of lenalidomide’s mechanism of action is shown in
Figure 2. In solid tumors, lenalidomide proved to have a
good safety proﬁle both in monotherapy and in combination
with chemotherapy showing results in terms of antitumor4 Journal of Oncology
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Figure 3: Proposed mechanism of the tumor homing properties of NGR-TNF. Ultra low dose NGR-TNF can interact more eﬃciently with
CD13-positive tumor vessel, compared to CD13-negative normal vessels, by virtue of high avidity interactions of the CNGRC domain with
CD13 and of the TNF domain with TNF receptors (TNF-Rs), thereby triggering local activation of endothelial cells, and inducing leukocyte
adhesion molecules, cytokine secretion, procoagulant activity, and apoptosis.
activity in several tumor types and also in NSCLC [63–67].
In fact, Miller et al. tested the feasibility of lenalidomide at a
dose escalated from 5 to 10 to 25mg/day in 20 patients with
solidtumorsrefractorytostandardtreatment[64].Moderate
dose-dependent and reversible haematological toxicity was
observed. One partial response and three stable diseases were
documented; of these patients three had NSCLC diagnosis.
This study recommended 25mg/day, orally, of lenalidomide
as single agent for 4 weeks followed by 2-week rest period.
Similarly, Kalmadi et al. explored safety and tolerability of
lenalidomide in association with docetaxel and carboplatin
in14patientswithadvancedsolidtumors[67].Notreatment
related deaths or irreversible toxicities were recorded. Five
patients achieved partial response; 5 out of 9 patients had
NSCLC. Docetaxel (60mg/m2)a n dc a r b o p l a t i n( A U C6 )o n
day 1 with lenalidomide 5mg daily orally for 2 weeks of a
21 day cycle was the maximum tolerated dose without the
use of prophylactic growth factors. Clinically, lenalidomide
shows a diﬀerent and more manageable toxicity proﬁle
compared to thalidomide, causing greater haematological
toxicity (neutropenia and thrombocytopenia) but much less
neurological toxicity [49].
4. NGR-TNF
NGR-TNF is an engineered TNF derivative with improved
neovasculaturehomingproperties.Thisdrug,developedand
initially tested at our Institute, is made of tumor necrosis fac-
tor α (TNF) fused to CNGRC, a peptide ligand of aminopep-
tidase N (CD13) overexpressed in tumor neovasculature
[68–70]. A schematic representation of this drug and of
the potential mechanism underlying its improved avidity
for tumor blood vessels is shown in Figure 3. Experiments
in animal models have shown that NGR-TNF, because of
its tumor vasculature homing properties, is endowed of
greater therapeutic activity and lower toxicity than TNF,
enabling systemic administration of therapeutic doses [68,
71]. NGR-TNF can promote antitumor responses primarily
by damaging the tumor vasculature. This provides the
rationale for using NGR-TNF as a single agent. In addition,
it has been demonstrated that ultra-low doses of NGR-
TNF (picograms/mouse) are suﬃcient to alter permeability
in tumor vessels of tumor-bearing mice and improve the
penetration of various chemotherapeutic drugs in tumor
tissues, including melphalan, doxorubicin, cisplatin, gemc-
itabine, and paclitaxel [71–73]. Thus, NGR-TNF may have
a dual pharmacological eﬀects, acting both as a vascular
damaging agent and as an enhancer of chemotherapy. In
principle, NGR-TNF could be exploited either to improve
the penetration of conventional doses of chemotherapeutic
drugs in tumors, favoring their local antitumor and immune
adjuvant eﬀects, or to reduce the dose of chemotherapeutic
drugs and their toxicity, including that against cells of the
immune system. This combined strategy might also beneﬁt
from the ability of TNF to promote anti-tumor immune
responses [74, 75]. Interestingly, targeted delivery of TNF
alone or in association with chemotherapy has been shown
to cure tumors in animal models and to induce protective
immunity [68]. This suggests that the immune response,
and in particular T-cell dependent mechanisms, represent
an important arm of NGR-TNF activity. TNF targeted to
vessels might also enhance the production of endothelial
immuneregulating cytokines or chemokines and/or upregu-
late endothelial adhesion molecules, favoring extravasation
of immune cells, and improving the ability of the immuneJournal of Oncology 5
system to cope with residual tumor cells [76]. A schematic
representation of NGR-TNF mechanism of action is shown
in Figure 3.
Various Phase I and Phase II clinical studies have
been undertaken with NGR-TNF in solid tumors showing
manageable toxicity proﬁle and evidence of disease control,
particularly in hepatocarcinoma, pleural mesothelioma, and
colorectalcancer[77–80].Atourinstitution,wearecurrently
testing low-dose NGR-TNF both as a single agent and
in combination with chemotherapeutic agents, such as
antracyclines and cisplatin, in several solid tumors, such as
pleural mesothelioma, NSCLC and small cell lung cancer.
Further studies are warranted to conﬁrm NGR-TNF as a
treatment option for NSCLC patients.
5. Conclusions
Standard treatment options for NSCLC patients, who are
mostly diagnosed in advanced stage of disease, often lead
to disappointing results. Immunotherapy is a promising
approach in several tumors and preliminary but promis-
ing data are arising also for lung cancer. Despite initial
attempts to treat NSCLC with immunomodulatory agents
were unsuccessful, the development of new drugs endowed
of immunomodulatory and antivascular activity have stim-
ulated further clinical studies. The ﬁrst agent we focused
on (PF-3512676) is an example of an immunomodulatory
agent with modest antivascular activity. Unfortunately, also
this drug eventually turned out to be ineﬀective in large
phaseIIItrialsforadvancedNSCLC.However,thepromising
early ﬁndings, in terms of eﬃcacy and toxicity, obtained with
lenalidomide and NGR-TNF, that is, two immunomodula-
tory agents endowed with strong antivascular activity, may
suggest that these compounds could play a role in the treat-
ment of NSCLC, both as single agents and in combination
with chemotherapeutic drugs. These combinations could be
the key to move a step forward in improving prognosis in
NSCLC patients.
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